Tadalafil

This classification denotes a cgmp phosphodiesterase inhibitor with the molecular formula C22H19N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 742SXX0ICT, chemically known as pyrazino(1,2:1,6)pyrido(3,4-b)indole-1,4-dione,6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-, (6r-trans)- but generally known as tadalafil, which bears US NIH Compound Identifier 110635. European Medicines Agency schedules Tadalafil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12602MIG. The term TADALAFIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16., No. 1.2002, List 47). World Health Organization schedules tadalafil in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule tadalafil under HS 29349990 and SITC 51579. As of Q4 2014, TADALAFIL remains the US FDA Preferred Term for this commodity. Tadalafil bears US NLM identifiers UMLS ID C0967376 and NCI Concept Code C47743. SMILES: O=C1N(CC(=O)N2C1CC1C([NH]C3C1CCCC3)C2C1CC2OCOC2CC1)C.